Search

The purpose of this study is to apply the Jengkol (Pithecellobium jiringa) peel like an iron inhibitor in a 3% hydrochloric acid medium. In this study, Jengkol peel is applied in powder form, concentrated extract form, and tannin form. The use of Jengkol peel as iron corrosion inhibitors in these three forms is made to see the ability of the three forms to act as inhibitors. The variations of inhibitor addition were 1g, 3g, 5g, 7g, and 9g for each form. Based on the results obtained, the three forms of inhibitors can act as good inhibitors for iron. Likewise, with the concentration of inhibitors used, the addition of 1g of Jengkol peel inhibitors for all forms has a good effect as an iron corrosion inhibitor. The results showed that the lowest corrosion rate on the iron plate was obtained by adding g of inhibitor and immersion time for 12 days for each form. The results achieved are not much different from the corrosion rate in the addition of inhibitors of 1g, 3g, 5g, and 7g for each form. This indicates that the addition of 1g inhibitors in each form can act to inhibit the iron corrosion rate.

Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. Better understanding of mesothelioma genomics and transcriptomics could advance novel therapies. We performed whole-exome and RNA-sequencing of germline and tumors of 122 patients with pleural, peritoneal, and tunica-vaginalis mesothelioma. We identify a 48 gene prognostic signature that is highly predictive of mesothelioma patient survival including CCNB1, whose expression is highly predictive of patient survival on its own. Using a synthetic-lethality (SL) based pipeline for analyzing the patients’ transcriptomic data, we identified SL-based signatures predictive of response to an anti-PD1 immune checkpoint inhibitor and combination therapies with pemetrexed. These SL-profiles successfully predict the overall patient-response observed across targeted, immuno- and chemotherapies in 11 independent mesothelioma clinical trials spanning 7 different treatments. These findings lay a basis for future studies aimed specifically at testing the ability of these SL profiles to serve as treatment biomarkers in mesothelioma.